Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immunotherapy Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03835533
What this trial is testing

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Parker Institute for Cancer Immunotherapy 43
Testing effectiveness (Phase 2)Ended earlyNCT04730349
What this trial is testing

Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Who this might be right for
EpendymomaEwing SarcomaHigh-grade Glioma+7 more
Bristol-Myers Squibb 15
Testing effectiveness (Phase 2)UnknownNCT00856804
What this trial is testing

Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance

Who this might be right for
Hepatitis C
Valme University Hospital 10
Large-scale testing (Phase 3)Looking for participantsNCT07365995
What this trial is testing

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
BioNTech SE 736
Testing effectiveness (Phase 2)Study completedNCT00001430
What this trial is testing

Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Who this might be right for
Hodgkin's DiseaseNon Hodgkin's Lymphoma
National Cancer Institute (NCI) 49
Early research (Phase 1)Ended earlyNCT03792841
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer
Amgen 212
Post-approval studies (Phase 4)Looking for participantsNCT05493267
What this trial is testing

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Who this might be right for
MDR-TBImmunotherapy
Shanghai Pulmonary Hospital, Shanghai, China 30
Not applicableEnrolling By InvitationNCT06647836
What this trial is testing

The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

Who this might be right for
Squamous Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301
What this trial is testing

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Who this might be right for
Small Cell Lung Cancer Extensive StageResistance to Immunotherapy
First Affiliated Hospital of Wannan Medical College 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03813394
What this trial is testing

Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

Who this might be right for
Locally Recurrent CancerMetastatic Nasopharyngeal Cancer
National University Hospital, Singapore 48
Testing effectiveness (Phase 2)Study completedNCT01867333
What this trial is testing

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Study completedNCT01804465
What this trial is testing

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

Who this might be right for
Prostate Cancer
University of California, San Francisco 50
Testing effectiveness (Phase 2)Study completedNCT03338790
What this trial is testing

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb 292
Testing effectiveness (Phase 2)Looking for participantsNCT07288034
What this trial is testing

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Who this might be right for
Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
City of Hope Medical Center 535
Testing effectiveness (Phase 2)Study completedNCT04717154
What this trial is testing

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Radboud University Medical Center 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164690
What this trial is testing

Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy

Who this might be right for
Esophageal AdenocarcinomaRadiotherapy
Fudan University 32
Early research (Phase 1)Not Yet RecruitingNCT07772882
What this trial is testing

Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Who this might be right for
Platinum Resistant Ovarian CancerFallopian Tube CancersPeritoneal Carcinoma
Rebecca Arend 24
Testing effectiveness (Phase 2)Looking for participantsNCT07306624
What this trial is testing

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
STCube, Inc. 62
Testing effectiveness (Phase 2)Study completedNCT03570619
What this trial is testing

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Who this might be right for
Metastatic Castration Resistant Prostate CancerMetastatic CancerSolid Tumor
University of Michigan Rogel Cancer Center 56
Early research (Phase 1)Ended earlyNCT04261439
What this trial is testing

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Who this might be right for
In Escalation: All Patients With Solid Tumors and LymphomaIn Expansion: Melanoma, Non-small Cell Lung Cancer
Novartis Pharmaceuticals 60
Next Page